Compass Pathways shares are trading lower after the company announced it pushed its topline data readout from its COMP005 Phase 3 trial to Q2 2025 and its COMP006 data will be announced after the 26-week time point.
Portfolio Pulse from Benzinga Newsdesk
Compass Pathways shares declined after the company delayed the topline data readout for its COMP005 Phase 3 trial to Q2 2025 and announced that COMP006 data will be available after the 26-week time point.
October 31, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Compass Pathways shares dropped due to the delay in the topline data readout for its COMP005 Phase 3 trial to Q2 2025, and the announcement that COMP006 data will be released after the 26-week time point.
The delay in the COMP005 Phase 3 trial data readout to Q2 2025 likely caused investor concern, leading to a drop in share price. The announcement of the COMP006 data release after the 26-week time point adds to the uncertainty, impacting short-term investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100